Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Jing Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8181-8159; OpenAlex author ID A5101446656, A5122593330. Sources: OpenAlex.

Their work

Papers
28 (first author 2, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
78
Papers, trials and grants by year

2014: 2 papers · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 2 papers · 2020: none · 2021: 3 papers · 2022: 5 papers · 2023: 5 papers · 2024: 7 papers · 2025: none · 2026: 2 papers

Papers 28

  1. KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy. Co-author DOI 10.1136/gutjnl-2025-336277↗
  2. Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic-Epigenetic Rewiring. Co-author DOI 10.1158/2159-8290.cd-25-1627↗
  3. KLF15 suppresses stemness of pancreatic cancer by decreasing USP21-mediated Nanog stability. Co-author DOI 10.1007/s00018-024-05442-6↗
  4. Tumor-derived interleukin 35 mediates the dissemination of gemcitabine resistance in pancreatic adenocarcinoma. Co-author DOI 10.1038/s41388-024-02938-0↗
  5. Correction: BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis. Co-author DOI 10.1038/s41392-023-01721-z↗
  6. Targeting ESE3/EHF With Nifurtimox Inhibits CXCR2+ Neutrophil Infiltration and Overcomes Pancreatic Cancer Resistance to Chemotherapy and Immunotherapy. Co-author DOI 10.1053/j.gastro.2024.02.046↗
  7. BICC1 drives pancreatic cancer stemness and chemoresistance by facilitating tryptophan metabolism. Co-author DOI 10.1126/sciadv.adj8650↗
  8. CD64+ fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-l… Co-author DOI 10.1136/gutjnl-2024-332371↗
  9. Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial. Co-author DOI 10.3892/ol.2024.14293↗
  10. BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis. Co-author DOI 10.1038/s41392-023-01478-5↗
  11. SDCBP promotes pancreatic cancer progression by preventing YAP1 from β-TrCP-mediated proteasomal degradation. Co-author DOI 10.1136/gutjnl-2022-327492↗
  12. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis. Last author DOI 10.1186/s13046-023-02671-8↗
  13. Artificial intelligence-based comprehensive analysis of immune-stemness-tumor budding profile to predict survival of patients with pancreatic adenocarcinoma. Co-author DOI 10.20892/j.issn.2095-3941.2022.0569↗
  14. Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma. Co-author DOI 10.20892/j.issn.2095-3941.2023.0039↗
  15. Genome-wide CRISPR screen identifies MTA3 as an inducer of gemcitabine resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2022.215864↗
  16. ESE3-positive PSCs drive pancreatic cancer fibrosis, chemoresistance and poor prognosis via tumour-stromal IL-1β/NF-κB/ESE3 signalling axis. Co-author DOI 10.1038/s41416-022-01927-y↗
  17. BZW1 Facilitates Glycolysis and Promotes Tumor Growth in Pancreatic Ductal Adenocarcinoma Through Potentiating eIF2α Phosphorylation. Co-author DOI 10.1053/j.gastro.2021.12.249↗
  18. ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4. First author DOI 10.1136/gutjnl-2020-321952↗
  19. Proscillaridin A induces mitochondrial damage and autophagy in pancreatic cancer and reduces the stability of SMAD4 in Panc-1 cells. Co-author DOI 10.21037/atm-22-1085↗
  20. Leukemia inhibitory factor is a novel biomarker to predict lymph node and distant metastasis in pancreatic cancer. Co-author DOI 10.1002/ijc.33291↗
  21. PERK-eIF2α-ERK1/2 axis drives mesenchymal-endothelial transition of cancer-associated fibroblasts in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2021.05.021↗
  22. A Glycolysis-Related Gene Signature Predicting Survival in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001777↗
  23. A feature-based analysis identifies COL1A2 as a regulator in pancreatic cancer. First author DOI 10.1080/14756366.2018.1484734↗
  24. Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1084/jem.20180749↗
  25. Overexpression of Topoisomerase 2-Alpha Confers a Poor Prognosis in Pancreatic Adenocarcinoma Identified by Co-Expression Analysis. Co-author DOI 10.1007/s10620-017-4718-4↗
  26. K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis. Co-author DOI 10.1007/s12032-016-0777-1↗
  27. Efficacy of percutaneous transhepatic cholangiodrainage (PTCD) in patients with unresectable pancreatic cancer. Last author DOI 10.1007/s13277-013-1363-1↗
  28. The outcome of cryoablation in treating advanced pancreatic cancer: a comparison with palliative bypass surgery alone. Last author DOI 10.1111/1751-2980.12170↗

Closest collaborators

The 25 strongest of 78 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jihui Hao · 17 shared papers, 2019–2026 · strength 2.59
  2. Chongbiao Huang · 16 shared papers, 2019–2026 · strength 2.31
  3. Song Gao · 16 shared papers, 2014–2026 · strength 2.19
  4. Tiansuo Zhao · 15 shared papers, 2019–2026 · strength 2.18
  5. Xiuchao Wang · 14 shared papers, 2019–2026 · strength 2.01
  6. Shengyu Yang · 13 shared papers, 2019–2026 · strength 1.91
  7. Tianxing Zhou · 10 shared papers, 2019–2026 · strength 1.60
  8. Yongjie Xie · 8 shared papers, 2022–2026 · strength 1.33
  9. Wenna Jiang · 8 shared papers, 2019–2024 · strength 1.15
  10. Huizhi Sun · 6 shared papers, 2021–2024 · strength 0.91
  11. Danqi Fu · 5 shared papers, 2019–2024 · strength 0.65
  12. Zengxun Li · 4 shared papers, 2022–2024 · strength 0.64
  13. Yukuan Feng · 3 shared papers, 2024–2026 · strength 0.62
  14. Chao Xu · 3 shared papers, 2023–2024 · strength 0.49
  15. Yifei Wang · 2 shared papers, 2026 · strength 0.45
  16. Chuntao Gao · 3 shared papers, 2021–2023 · strength 0.38
  17. Jun Yu · 2 shared papers, 2024–2026 · strength 0.36
  18. Quan Man · 2 shared papers, 2023 · strength 0.30
  19. Xiufeng Zhang · 2 shared papers, 2023–2024 · strength 0.29
  20. Fanjie Jin · 2 shared papers, 2021–2022 · strength 0.24
  21. Wenrun Cai · 2 shared papers, 2021–2022 · strength 0.24
  22. Qiu Zhao · 2 shared papers, 2017–2021 · strength 0.23
  23. Zhi Ji · 1 shared paper, 2026 · strength 0.20
  24. Qingxiao Fang · 1 shared paper, 2026 · strength 0.20
  25. Shangheng Shi · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.